Search Results
Mar 25, 2026, 08:00 ET Lowe's Rolls Out Spring Savings and Free Same-Day Delivery on Mulch
Miracle Gro 25-QT Organic Potting Mix or Miracle Gro 1.5-CF Raised Bed Soil2 for $20 12-PK Annuals (valid in-store only, items vary by location)Seasonal Save $50 on
More news about: Lowe's Companies, Inc.
Mar 25, 2026, 02:32 ET BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States
BGM0504 shown to be generally well tolerated Overall safety, pk, and efficacy profile supports once-daily oral dosingSUZHOU, China, March 25, 2026 /PRNewswire/
More news about: BrightGene
Mar 24, 2026, 10:00 ET Q2BI Marks the Independent Launch of JDIX and a New Chapter in Clinical Data Intelligence
company specializing in biometrics, data science, and AI-enabled clinical solutions. With deep expertise across clinical statistics, data management, PK/PD, and regulatory submissions, Q2BI partners with biopharma and AI companies to accelerate the development of innovative medicines.For more information,
More news about: Q-Square Business Intelligence (Q2BI)
Mar 24, 2026, 08:13 ET Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations.Safety and tolerability findings included:No serious adverse events (0%)No dose-limiting
More news about: Hoth Therapeutics, Inc.
Mar 24, 2026, 03:43 ET DualityBio (9606.HK) Announces 2025 Annual Results
Immunology Conference ("AIC 2025"). The results showed that DB-2304 was generally safe and well-tolerated in healthy subjects, with linear Pharmacokinetics ("PK") characteristics, and could effectively bind to the target, verifying its pharmacologic mechanism.DB-1418/AVZO-1418 (EGFR×HER3 BsADC):
More news about: Duality Biotherapeutics, Inc.
Mar 23, 2026, 23:30 ET Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)
high degree of analytical and clinical pharmacokinetic (PK) similarity demonstrated between HD204 and Avastin. SAMSON-II results strengthen the collective global experience showing that sensitive analytical characterization and comparative clinical PK studies can reliably predict equivalent clinical performance
More news about: Prestige Biopharma
Mar 23, 2026, 09:00 ET Stepping Up the Softness: Pair of Thieves Brings Upgraded Basics to Target
Boxer Briefs ($26.99/3pk) – Luxuriously soft, breathable boxer briefs crafted from bamboo-derived rayon with a refined fit and comfort-driven design. Fade resistant, durable,
More news about: Pair of Thieves
Mar 23, 2026, 07:00 ET BioLineRx Reports 2025 Financial Results and Provides Corporate Update
progressive GBM and other high-grade gliomas. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Data from the Phase 1 part of the trial are anticipated in H1 2027.The Phase 2a expansion part of the trial is
More news about: BioLineRx Ltd.
Mar 22, 2026, 23:14 ET Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
placebo-controlled, single-ascending-dose (SAD) study, 50 healthy adult subjects were enrolled to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of HBM9378. The dose-escalation study enrolled ten healthy subjects per cohort (20 mg, 60 mg, 200 mg, 600 mg, and 900 mg), with eight
More news about: Harbour BioMed
Mar 19, 2026, 10:00 ET FLYING SAUCERS CRASH INTO CARVEL SHOPPES TO CELEBRATE THE 75TH ANNIVERSARY OF AN ICE CREAM ICON
last. Limit one per person. Not valid with any other offer or reward. Void where prohibited.** Offer valid for select Fudgie Fanatics for one (1) 6pk of Flying Saucers for $7.50 (plus tax) valid through 3/22/26 in shoppe only at participating locations. Single use. Must present coupon at checkout.
More news about: Carvel
Mar 18, 2026, 09:00 ET New Report: Religious Participation Linked to Stronger Academic Outcomes for Students
of religious faith depend on one's level of observance, evidence suggests that nonbelievers can also benefit from religious faith as a resource in the PK–12 education ecosystem. Characterized as "abiders," students with high levels of religiosity experience the greatest benefits.Organized into the
More news about: Wheatley Institute
Mar 18, 2026, 08:00 ET MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726. Primary endpoints include monitoring adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs leading to treatment discontinuation. Secondary and exploratory endpoints include PK profiling and evaluation
More news about: MetaVia Inc.
Mar 18, 2026, 08:00 ET Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
NCT05848739) is a first-in-human, open-label, Phase 1/2 dose escalation and expansion study designed to determine the safety, tolerability, PK, PD and early efficacy of ST316. The Phase 1 dose escalation portion of the study tested various dose levels of ST316 in patients with selected advanced
More news about: Sapience Therapeutics, Inc.
Mar 18, 2026, 06:00 ET IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
7; and IDE892, an MTA-cooperative inhibitor of PRMT5. The company is currently conducting Phase 1 clinical studies to evaluate safety, tolerability, PK and efficacy of these three programs across a broad range of large solid tumor indications, including lung, colorectal, pancreatic, breast, and prostate
More news about: IDEAYA Biosciences, Inc.
Mar 17, 2026, 16:46 ET Brenig Therapeutics Announces Oral Presentation of Phase 1 Data for BT-267 at AD/PD™ 2026, and Provides Updates on BT-409, its NLRP3 Inhibitor Program
BT-409 Phase 1 trial underway.The presentation will highlight emerging clinical data evaluating the safety, tolerability, pharmacokinetics (PK), and central nervous system (CNS) penetration of BT-267 in healthy volunteers.Presentation DetailsTitle: Phase 1 Study
More news about: Brenig Therapeutics Inc
Mar 17, 2026, 07:43 ET Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD
interstitial lung disease (PH-ILD) in Q1 2027. The approved study is a Phase I, open-label, randomized, two-period crossover pharmacokinetic (PK) trial in 14 healthy adult volunteers. The study will evaluate steady-state pharmacokinetics following seven days of repeat oral dosing of CS014 compared
More news about: Cereno Scientific
Mar 17, 2026, 07:39 ET Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD
interstitial lung disease (PH-ILD) in Q1 2027. The approved study is a Phase I, open-label, randomized, two-period crossover pharmacokinetic (PK) trial in 14 healthy adult volunteers. The study will evaluate steady-state pharmacokinetics following seven days of repeat oral dosing of CS014 compared
More news about: Cereno Scientific
Mar 16, 2026, 08:00 ET Alar Announced Buprenorphine Injectable, ALA-1000, Demonstrated Long-Term Efficacy and Favorable Safety Profile in Canine Osteoarthritis Pain Management
results of ALA-1000 study in client-owned dogs with osteoarthritis. The results demonstrate the efficacy, safety, tolerability, and pharmacokinetic (PK) durability for ALA-1000, a subcutaneous buprenorphine LAI, at target dose in dogs with osteoarthritis-associated pain. The primary endpoint was
More news about: Alar Pharmaceuticals Inc.
Mar 16, 2026, 08:00 ET Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab, AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and
More news about: Celltrion
Mar 12, 2026, 08:00 ET Cozeware Kick Off "Spring Wishes" with Mega Discounts on Ductless ACs and Participates in TikTok Pop-Up Event in NYC
Register hereTop-tier influencers will lead live "PK" challenges and product showcases. Attendees can experience Cozeware's cooling power firsthand and unlock exclusive rewards, including official shop
More news about: Cozeware
Mar 10, 2026, 08:00 ET Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
Receptor Modulating Neuroactive Steroid (NAS) Anti-seizure Medication (ASM) Candidate for Women with Epilepsy (WWE)Clinical Pharmacokinetics (PK) and Tolerability of a Novel Oral GABAA Receptor Positive Allosteric Modulating (PAM) Candidate for EpilepsyBased on FDA
More news about: Lipocine Inc.
Mar 09, 2026, 08:01 ET Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
both Clinical Cure and Sustained Clinical Cure.In the Phase 2 clinical trial (both trial segments), the Company also evaluated pharmacokinetics (PK) and microbiome changes and test for anti-recurrence microbiome properties, including the change from baseline in alpha diversity and bacterial abundance,
More news about: Acurx Pharmaceuticals, Inc.
Mar 09, 2026, 08:00 ET AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous ABBV-295, in adults with a mean body mass index (BMI) of less than 30 kg/m2. ABBV-295 is a long-acting
More news about: AbbVie
Mar 05, 2026, 10:02 ET US Leaders in Advanced Air Mobility to Convene at LIFT Summit in Monterey
and Climate InnovationEmily Warren, Deputy Sec. for Innovative Mobility, California State Transportation AgencyParimal Kopardekar (PK), Program Dir., Airspace Operations and Safety Program, NASAHuy Tran, Dir. of Aeronautics at NASA Ames Research CenterSusan Shaheen,
More news about: Monterey Bay DART
Mar 05, 2026, 01:24 ET Fapon Biopharma präsentiert CD3/TCR VHH TCE-Plattform der nächsten Generation auf dem 19. Annual European Life Sciences CEO Forum
Translation. Die Plattform hat bereits erfolgreich die Evaluierung abgeschlossen und dabei eine überlegene Wirksamkeit und Sicherheit sowie eine vorhersagbare PK/PD in Studien mit Mäusen und NHP gezeigt.Fapon Biopharma verfügt über ein hervorragendes CMC-Profil und Flexibilität bei der Formatierung von
More news about: Fapon Biopharma